IL-4 enhances expression and function of surface IgM in CLL cells

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• B-cell receptor (BCR) kinase inhibitors are key in treating chronic lymphocytic leukemia (CLL).
• Interleukin-4 (IL-4) is a cytokine known to protect B cells and modulate surface immunoglobulin M (sIgM) expression.

Purpose of the Study:

• To investigate the role of IL-4 in modulating BCR signaling and its impact on CLL treatment efficacy.
• To explore the potential of targeting IL-4 pathways in CLL therapy.

Main Methods:

• In vitro analysis of IL-4 effects on sIgM expression in normal and CLL B cells.
• Measurement of BCR signaling activity (calcium mobilization) and gene/protein expression (CD79B).
• Assessment of IL-4's impact on the efficacy of BCR kinase inhibitors (idelalisib, ibrutinib).

Main Results:

• IL-4 increased sIgM expression and BCR signaling in CLL cells, particularly those with unmutated V-genes.
• IL-4 pretreatment reduced the inhibitory effect of idelalisib and ibrutinib on BCR signaling.
• IL-4 decreased CXCR4 and CXCR5 expression, potentially promoting B-cell retention in lymph nodes.
• IL-4 effects were mediated via JAK3/STAT6 signaling.

Conclusions:

• IL-4 can enhance BCR signaling in CLL, potentially conferring resistance to targeted therapies.
• IL-4 may play a role in B-cell retention within lymph nodes in CLL.
• Combination therapy with JAK inhibitors and BCR kinase inhibitors may be a promising strategy for CLL treatment.